Novartis Pharmaceuticals Corp
East Hanover, New Jersey, 07936, United States
NCT Number: NCT00350168
The purpose of this study is to evaluate the blood pressure lowering effects of a valsartan/amlodipine combination treatment and amlodipine monotherapy for the treatment of stage II hypertensive patients (MSSBP ≥ 160 mmHg).
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
East Hanover, New Jersey, 07936, United States
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Novartis
Industry
An 8-week Multicenter Study to Evaluate the Efficacy and Safety of Orally Administered Valsartan/Amlodipine Combination Based Therapy Versus Amlodipine Monotherapy in Patients With Stage II Hypertension
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05180045
Cardiovascular Diseases, High Blood Pressure
Washington D.C., District of Columbia, United States
View Trial DetailsNCT02692846
Aortic Stenosis, Supravalvular, Aortic Valve Disease
Bethesda, Maryland, United States
View Trial DetailsNCT00837122
Cardiovascular Diseases, Diabetes
Accra, Ghana
View Trial DetailsNCT06845007
Cardiovascular Diseases, Hypertension
Lisbon, Lisbon District, Portugal
View Trial Details